ADAM SCHMUCKLER: Open Payments
NPI 1902903990 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,262 in 159 payments from 45 companies in 2025. Trend: 2023 $2,575 · 2024 $3,486 · 2025 $4,262
Food & beverage: $4,245Education: $17
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 20 | $442 |
| PFIZER INC. | 16 | $403 |
| AstraZeneca Pharmaceuticals LP | 14 | $388 |
| Janssen Biotech, Inc. | 8 | $328 |
| BeOne Medicines USA, Inc. | 6 | $244 |
| Genentech USA, Inc. | 7 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $155 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $143 |
| Daiichi Sankyo Inc. | 4 | $114 |
| E.R. Squibb & Sons, L.L.C. | 4 | $113 |
Products named: TEVIMBRA, RYBREVANT, Enhertu, Nubeqa, PLUVICTO, VPRIV, KIMMTRAK, LYNPARZA.
Industry payments across MD — which companies pay providers there.
